

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 February 2020 (27.02.2020)



(10) International Publication Number
WO 2020/038352 A1

(51) International Patent Classification:

A61K 48/00 (2006.01) C12N 15/864 (2006.01)
C12N 15/66 (2006.01)

(21) International Application Number:

PCT/CN2019/101538

(22) International Filing Date:

20 August 2019 (20.08.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201810948193.1 20 August 2018 (20.08.2018) CN
PCT/CN2018/103937
04 September 2018 (04.09.2018) CN
201811221305.X 19 October 2018 (19.10.2018) CN
201811230856.2 22 October 2018 (22.10.2018) CN
PCT/CN2018/113799
02 November 2018 (02.11.2018) CN
PCT/CN2018/118662
30 November 2018 (30.11.2018) CN
PCT/CN2019/070461
04 January 2019 (04.01.2019) CN

(71) Applicant: **WUHAN NEUROPTH BIOLOGICAL TECHNOLOGY LIMITED COMPANY** [CN/CN]; C270-271, 3rd Floor, B1, R&D Building, Project B, C, D Area, Wuhan National Bio Industry Base, No. 666 Hi-tech Avenue, East Lake New Technology Development Zone, Wuhan, Hubei 430060 (CN).

(72) Inventor: **LI, Bin**; C270-271, 3rd Floor, B1, R&D Building, Project B, C, D Area, Wuhan National Bio Industry Base, No. 666 Hi-tech Avenue, East Lake New Technology Development Zone, Wuhan, Hubei 430060 (CN).

(74) Agent: **METIS IP (CHENGDU) LLC**; Room 808, 8th Floor, Building B7, Block D, Tianfu Jingrong Center, No.

99 West Section of Hupan Road, Tianfu New District, Chengdu, Sichuan 610213 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY




FIG. 8

(57) Abstract: Provided is a recombinant nucleic acid, comprising: a mitochondrial targeting sequence; a mitochondrial protein coding sequence, wherein said mitochondrial protein coding sequence encodes a polypeptide comprising a mitochondrial protein; and a 3'UTR nucleic acid sequence. Also provided are a pharmaceutical composition comprising the recombinant nucleic acid and a method of treating Leber's hereditary optic neuropathy (LHON) using the pharmaceutical composition.

WO 2020/038352 A1